

November 1, 2023

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir,

Re: Script Code 526139

Subject: Intimation on Canine Insulin study results.

This is to inform you that NiedlFree Technologies Pvt Ltd, a company associated with Transgene Biotek, has undertaken to revive and advance the oral / nasal delivery technology initiated by Transgene Biotek several years ago but unable to advance due to several challenges. NiedlFree has reported impactful results on a Canine Insulin study conducted at a renowned CDMO company on oral and nasal Insulin delivery.

The management of NiedlFree has also informed Transgene that with the Canine Insulin results demonstrating relative bio-availability in excess of 90%, a result that is unparalleled so far, has opened a dialogue with animal healthcare companies in Europe/USA towards monetization of oral Insulin in the pet-care markets.

It is relevant to note the reported global diabetic market in pet care segment as Rs.16,000 Crs approximately in 2022.

Further, with these results in higher animals demonstrating excellent efficacy and safety data, it will have de-risking outlook going forward towards human clinical studies with targeted date to receive marketing approvals for Oral Insulin by 2025-26.

This is for your information and records only.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED



DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR